Meeting NewsVideo

VIDEO: AstraZeneca executive highlights ‘extensive’ development program for acalabrutinib in CLL

CHICAGO — Michelle Dawson, PhD, U.S. medical affairs franchise head for hematology at AstraZeneca, spoke with HemOnc Today at ASCO Annual Meeting about key data related to acalabrutinib for the treatment of chronic lymphocytic leukemia.

Acalabrutinib (Calquence, AstraZeneca) — a Bruton tyrosine kinase inhibitor — is approved in the United States for treatment of adults with relapsed or refractory mantle cell lymphoma. The agent is under investigation for CLL and other blood cancers.

Dawson highlighted results of the CL-003 study, which evaluated acalabrutinib plus obinutuzumab (Gazyva, Genentech) for patients with treatment-naive or relapsed/refractory CLL.

She also highlighted the company’s development program for acalabrutinib, which consists of four phase 3 trials.

“We’re also looking at other B-cell malignancies as we’re moving forward, including diffuse large B-cell lymphoma,” Dawson told HemOnc Today. “We also have a very rich pipeline, and some of that is coming together already into the phase 2 setting, where we are looking at acalabrutinib in combination with really novel agents.” – by Mark Leiser

CHICAGO — Michelle Dawson, PhD, U.S. medical affairs franchise head for hematology at AstraZeneca, spoke with HemOnc Today at ASCO Annual Meeting about key data related to acalabrutinib for the treatment of chronic lymphocytic leukemia.

Acalabrutinib (Calquence, AstraZeneca) — a Bruton tyrosine kinase inhibitor — is approved in the United States for treatment of adults with relapsed or refractory mantle cell lymphoma. The agent is under investigation for CLL and other blood cancers.

Dawson highlighted results of the CL-003 study, which evaluated acalabrutinib plus obinutuzumab (Gazyva, Genentech) for patients with treatment-naive or relapsed/refractory CLL.

She also highlighted the company’s development program for acalabrutinib, which consists of four phase 3 trials.

“We’re also looking at other B-cell malignancies as we’re moving forward, including diffuse large B-cell lymphoma,” Dawson told HemOnc Today. “We also have a very rich pipeline, and some of that is coming together already into the phase 2 setting, where we are looking at acalabrutinib in combination with really novel agents.” – by Mark Leiser

    See more from ASCO Annual Meeting